GlassScriptPhysician profile
Jacob Austin Harrison
NPI 1083438097
$667.00
in general payments reported to CMS, 2019-2025
13 companies · $667 in 2025
The $667 reported for 2025 was more than what 81% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $667.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $144.01 | 2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $128.45 | 2025 | Amvuttra |
| Edwards Lifesciences Corporation | $117.14 | 2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $67.17 | 2025 | Ffrangio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.24 | 2025 | Jardiance |
| United Therapeutics Corporation | $28.87 | 2025 | Tyvaso |
| Pfizer INC. | $27.45 | 2025 | |
| Cvrx, INC. | $24.43 | 2025 | Barostim Neo System |
| Angiodynamics, INC. | $21.33 | 2025 | Alphavac |
| Boston Scientific Corporation | $20.40 | 2025 | Avvigo Guidance System |
| Novartis Pharmaceuticals Corporation | $20.10 | 2025 | |
| Cleerly, INC. | $18.21 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Astrazeneca Pharmaceuticals LP | $17.20 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.